Triple
T4850383
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Pfizer |
E108398
|
entity |
| Predicate | developed |
P73
|
FINISHED |
| Object |
Xeljanz
Xeljanz is an oral Janus kinase (JAK) inhibitor medication used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
|
E474935
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69bd440a89548190a5f14ba6da6b97dc |
elicitation | completed |
| NER | batch_69bd6d1e5cf08190bd6b6a524748f170 |
ner | completed |
| NED1 | batch_69be5cdefda8819095fbc04446bf32f5 |
ned_source_triple | completed |
| NED2 | batch_69be6159ff7c8190baa116240f76dea5 |
ned_description | completed |
| NEDg | batch_69be5dadcec88190bf9a272c4a9aef9a |
nedg | completed |
Created at: March 20, 2026, 1:25 p.m.